Insulin-like growth factor-1 receptor (IGF-1R) is a potential therapeutic target, because it is overexpressed in many cancers, AD, traumatic brain injury, amyotrophic lateral sclerosis (ALS), Friedreich ataxia and aging. This evidence concerns the gene IGF1R and Friedreich ataxia.